Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.48 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.47 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29895989 | 0.81 | LPAR1 (0.47) | LPAR1LPAR3POLB | |
| SCHEMBL9915902 | 0.76 | RORC (0.49) | LPAR1LPAR3SMN1; SMN2LRRK2 | |
| SCHEMBL29895995 | 0.76 | LPAR1 (0.53) | LPAR1LPAR3LRRK2 | |
| SCHEMBL1011910 | 0.76 | KDM4E (0.50) | GAATHRBRAB9AKDM4EHTT | |
| SCHEMBL28568899 | 0.75 | KLK7 (0.54) | LPAR1LPAR3HSD17B10KMT2AMEN1 | |
| SCHEMBL28571893 | 0.75 | KLK7 (0.54) | LPAR1LPAR3HSD17B10KMT2AMEN1 | |
| SCHEMBL29895983 | 0.74 | LPAR1 (0.51) | LPAR1LPAR3LRRK2 | |
| SCHEMBL28163574 | 0.74 | LPAR1 (0.54) | GAARAB9ALPAR1LPAR3FFAR2 | |
| SCHEMBL28163571 | 0.74 | LPAR1 (0.54) | GAARAB9ALPAR1LPAR3FFAR2 | |
| SCHEMBL29895998 | 0.74 | LPAR1 (0.51) | LPAR1LPAR3LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11427552-B2 | Heterocyclic compounds useful in the treatment of disease | EPIGEN BIOSCIENCES, INC. (US) | 2022-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11427552-B2 | Heterocyclic compounds useful in the treatment of disease | LPAR1, LPAR4, LPAR3 | GAA 4145/4885THRB 2829/4885RAB9A 981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.